prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |review

Key Point: After 6 weeks of treatment in the STELLAR trial, a significantly greater percentage of patients treated with rosuvastatin 10 mg, 20 mg, and 40 mg achieved optimal LDL-C of <100 mg/dL than patients treated with the same doses of atorvastatin, simvastatin, and pravastatin (P<.002).

53% of patients taking rosuvastatin 10 mg achieved an LDL-C <100 mg/dL, while only 18% of  patients taking atorvastatin 10 mg were able to reduce their LDL-C to <100. Mean baseline LDL-C levels ranged from 187 mg/dL to 194 mg/dL

Rosuvastatin 40 mg was associated with the highest percentage of patients who achieved an LDL-C of <100 mg/dL

80% of patients treated with rosuvastatin 40 mg achieved <100 mg/dL




Reference

McKenney J, Jones PH, Adamczyk MA, et al for the STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin and pravastatin in achieving lipid goals: results from the STELLAR trial.Curr Med Res Opin. 2003;19:557-566.